News

May 21, 2018May 21, 2018

Actemra Treatment Linked to Disease Remission in Systemic JIA, German Registry Shows

Treatment with Actemra (tocilizumab) is linked to favorable outcomes, namely disease inactivation and remission, in patients with systemic juvenile idiopathic arthritis, according to an analysis of a German autoinflammatory ... Read more

May 18, 2018May 18, 2018

FDA Approves Subcutaneous Form of Actemra for Active Polyarticular JIA

News

The U.S. Food and Drug Administration approved Genentech’s subcutaneous formulation of Actemra (tocilizumab) to treat patients 2 and older who have active polyarticular juvenile idiopathic arthritis (PJIA). The new ... Read more

May 14, 2018May 14, 2018

Tocilizumab Seen to Benefit Most Systemic JIA Patients in Real-life Setting, Study Shows

News

Tocilizumab, an approved therapy for children and adults with systemic juvenile idiopathic arthritis, is effective in real-life setting and shows evidence of benefiting most patients, according to a study done ... Read more

May 11, 2018May 11, 2018

Enbrel Biosimilar Seeks Approval in Japan to Treat Juvenile Idiopathic Arthritis

News

YL Biologics in collaboration with Kyowa, a subsidiary Lupin, are seeking approval from regulatory officials in Japan of YLB113, their potential treatment for patients with moderate-to-severe juvenile idiopathic arthritis and ... Read more

May 7, 2018May 7, 2018

Arthritis Foundation Launches ‘Let’s Get a Grip on Arthritis’ Campaign to Find a Cure

News

May is Arthritis Awareness Month, and the Arthritis Foundation has launched a national campaign challenging Americans to support the effort to help find a cure. Arthritis is the leading cause ... Read more

May 4, 2018May 4, 2018

Patient-Centered Outcomes Research Institute Approves $20 Million in New Research Funding

News

The Patient-Centered Outcomes Research Institute’s (PCORI) board of governors has approved more than $20 million in research funding to support four projects in various fields, including arthritis, irritable bowel disease, ... Read more

April 20, 2018April 20, 2018

Four Canadian Provinces Add Erelzi to Their Public Plans to Treat Inflammatory Diseases, Including Juvenile Arthritis

News

Manitoba, Saskatchewan, Alberta and Newfoundland are the most recent Canadian provinces to add Sandoz’s biosimilar Erelzi (etanercept) to their provincial medication plans for the treatment of several inflammatory diseases, ... Read more

April 16, 2018April 16, 2018

Mylan and Fujifilm Kyowa Kirin Partner to Bring Humira Biosimilar to Europe

News

Mylan is partnering with Fujifilm Kyowa Kirin Biologics to commercialize a biosimilar of Humira (adalimumab) in Europe, offering a new treatment option to patients with conditions like juvenile arthritis (JA). ... Read more

April 12, 2018April 12, 2018

Study Reveals Immune Processes Involved in Systemic Juvenile Arthritis

News

Anomalies in the number of immune cells and specific cellular signals are both linked to the severity of systemic juvenile idiopathic arthritis (JIA) symptoms, researchers in China found. According ... Read more

April 9, 2018April 9, 2018

JIA Classification Criteria Needs to Be Improved, Study Suggests

News

The study of a relatively large group of juvenile pediatric spondyloarthritis patients revealed there’s a need for more accurate classification criteria for disease identification. The study also showed that a ... Read more

Pin It on Pinterest